본문으로 건너뛰기
← 뒤로

Copper Transporter 1‑Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors.

2/5 보강
ACS pharmacology & translational science 📖 저널 OA 100% 2024: 4/4 OA 2025: 9/9 OA 2026: 8/8 OA 2024~2026 2026 Vol.9(4) p. 902-924 OA Trace Elements in Health
Retraction 확인
출처
PubMed DOI PMC OpenAlex 마지막 보강 2026-04-30
OpenAlex 토픽 · Trace Elements in Health Ferroptosis and cancer prognosis Metal complexes synthesis and properties

Mouawad R, Eisa NH, Balia A, Roy J, Neamati N

📝 환자 설명용 한 줄

Certain tumors are dependent on copper for proliferation, metastasis, and energy production, making them particularly susceptible to copper depletion.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Rima Mouawad, Nada H. Eisa, et al. (2026). Copper Transporter 1‑Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors.. ACS pharmacology & translational science, 9(4), 902-924. https://doi.org/10.1021/acsptsci.5c00651
MLA Rima Mouawad, et al.. "Copper Transporter 1‑Mediated Deregulation of Copper Homeostasis Impacts MYC and Oxidative Phosphorylation Pathways and Increases the Sensitivity of Tumor Cells to Complex I Inhibitors.." ACS pharmacology & translational science, vol. 9, no. 4, 2026, pp. 902-924.
PMID 41988364 ↗

Abstract

Certain tumors are dependent on copper for proliferation, metastasis, and energy production, making them particularly susceptible to copper depletion. Altering copper homeostasis has emerged as a promising strategy for treating these cancers. Previously, we synthesized novel compounds, JR4-187 (JR4) and JR5-26B (JR5), which demonstrated copper-dependent in vivo efficacy. RNA-seq analysis revealed that JR4 treatment in colon cancer cells leads to a marked downregulation of oxidative phosphorylation and MYC-targeted genes. Both JR4 and JR5 reduce MYC and NDUFS7 protein levels. Additionally, JR4 and JR5 increase tumor cell sensitivity to complex I inhibitors, including AGB-374, a novel NDUFS7 inhibitor that we developed. AGB-374 exhibited in vivo efficacy when administered orally, both as a single agent and in combination with JR5, in a mouse model of colon cancer. Our findings indicate a significant functional relationship between CTR1 and NDUFS7, providing a foundation for the development of new cancer therapies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기